Aquestive(US:AQST) TMX Newsfile·2026-03-08 14:20Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's New Drug Application for Anaphylm [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Aquestive between June 16, 2025, and January 8, 2026, to discuss their legal options [1]. - A federal securities class action has been filed against Aquestive, with a deadline of May 4, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that the company and its executives made false and misleading statements regarding the approval timeline for Anaphylm, leading to artificially inflated stock prices [4]. Group 2: Stock Price Impact - Following the announcement on January 9, 2026, regarding deficiencies identified by the FDA in the NDA for Anaphylm, Aquestive's stock price dropped by more than 37% on the same day [5]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].